OTC
0.09USD
0.00 (0.00%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Latest scored catalyst for SHIEF: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Market cap
91.6M
P/E
—
EPS
—
Beta
1.72
52W range
0.0521-0.1679
Day range
0.06–0.09
Open
0.06
Prev close
0.09
Volume
16.2K
Avg volume
28.4K
Dividend
0.00
IPO
2019-12-06
Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements. Its flagship product, Accrufer/Feraccru, offers an innovative, non-salt-based oral treatment specifically for adults suffering from iron deficiency, irrespective of whether anemia is present. Furthermore, the company is advancing PT20, a pioneering iron-based phosphate binder that has successfully concluded its pivotal Phase II trials for managing hyperphosphatemia in individuals with chronic kidney disease. This enterprise was founded in 2008 and maintains its headquarters in Gateshead, United Kingdom.
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Shield Therapeutics plc — not a sector bucket. Click an edge to see the articles that established the link.
